Cost-Effectiveness Analysis of Tocilizumab Subcutaneous As First Line Biologic Monotherapy for Rheumatoid Arthritis Management In Greece

Nov 1, 2015, 00:00 AM
10.1016/j.jval.2015.09.1971
https://www.valueinhealthjournal.com/article/S1098-3015(15)04047-4/fulltext
Section Title : Research Podium Presentations - Session 1 and Session 2
Section Order : 1865
First Page : A671
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)04047-4&doi=10.1016/j.jval.2015.09.1971
HEOR Topics :
Tags :
Regions :